The Japanese Society of Neuropsychopharmacology
Home Contact Us

The Japanese Society of Neuropsychopharmacology

Association for Supporting Academic Societies
5-3-13, Bunkyoku, Tokyo, 112-0012, Japan
Phone: +81-3-5981-6011
Fax: +81-3-5981-6012

Greeting from the President


On October 10, 2016, I became President of the Japanese Society of Neuropsychopharmacology (JSNP), and I would like to make an introductory speech.

JSNP was founded in 1971 as the Study Group of Neuropsychopharmacology. At the time, therapeutic 1st generation medications for the treatment of major mental disorders, such as depression and schizophrenia, had appeared. The group was initially founded as a discussion panel for both pharmacologists and psychiatrists who were interested in the "Mind and Drugs." This discussion group, which focused on translation from basic to clinical research, subsequently grew and later became the Japanese Society of Neuropsychopharmacology in 1985. Although had graduated from the Faculty of Engineering and was not initially in the mainstream of neuropsychopharmacology, I was guided by excellent collaborators who I met at JSNP. These experienced researchers and practitioners broadened my scope of research into basic brain science, translational research, and clinical research. I would like to give to JSNP as much as they gave me to contribute to advances in neuropsychopharmacology and overcoming mental and neurological disorders.

The internationalization of neuropsychopharmacology is proceeding. JSNP established the Asian College of Neuropsychopharmacology (AsCNP) in 2009 in collaboration with neuropsychopharmacology societies in major Asian countries. Prof. Shigeto Yamawaki, the President of JSNP at the time, played a major role in establishing AsCNP. Considering that Asia accounts for about 60% of the world’s population and its remarkable economic growth in recent years, a tremendous amount of central nervous system (CNS) medications will be needed in the near future. Together with AsCNP, JSNP will promote the development of CNS medications that are suitable for the Asian population and promote the proper use of pharmaceutical products. In 2019, the AsCNP Biennial Congress will be held again in Japan. The presence of Japan and Asia as a whole at the International College of Neuropsychopharmacology (CINP) is also growing. Prof. Yamawaki became the first Asian President of CINP in 2014. In 2016, I chaired the 46th JSNP Annual Meeting, which was held in Seoul in conjunction with the 30th CINP World Congress. During my term as President of JSNP, I would like to continue this trend of internationalization that former Presidents of JSNP encouraged, including Prof. Yamawaki and Prof. Jun Ishigooka.

One pillar of JSNP activities has been industry-academia-government collaborations. Despite the large number of patients with neuropsychiatric disorders who do not respond to existing therapies, many large pharmaceutical companies are withdrawing from the development of CNS medications. This leaves patients behind. To overcome this situation, JSNP launched the Translational Medical Science Committee to promote academia-industry cooperation. JSNP is also working with CINP to introduce the Public Private Partnership (PPP) system to this area. We hope that multiple PPPs will be launched in this 2-year term. We will continue to serve as an academic organization that contributes to society by preparing and revising pharmacotherapy guidelines and publishing statements related to regulatory affairs that were strongly promoted by the former President of JSNP, Prof. Ishigooka.

As a new project in the current 2-year term, we will promote the renewal of our official journal, which has been discussed for many years. This will be achieved mainly through the Publications Committee, the Public Relations Committee, and the Executive Committee. My aim is to transform our journal into one that meets the needs of JSNP members and domestic and international researchers. As an academic society that responds to the needs of many researchers and medical professionals who study and prescribe CNS medicines, we launched two task forces: the Membership Alliance Promotion Task Force and the Advanced Research Promotion Task Force, both of which will be instituted for 2 years. We also renewed the Pharmacist Affairs Working Group to respond to the needs of clinical pharmacists who deal with CNS medicines.

I would like to cooperate closely with Prof. Kazuyuki Nakagome, the Vice President of JSNP, to steadily advance these academic activities. I respectfully ask JSNP members and citizens for their support and cooperation in working with JSNP to achieve these goals.

Kazutaka Ikeda, Ph.D.
President of the Japanese Society of Neuropsychopharmacology